Latest news and press releases about Profusa, Inc. Common Stock (PFSA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.
Price
| Price | $1.78 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.00 |
| EV / EBITDA | -8.99 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 134.38% |
| Return on Invested Capital | 114.53% |
| Return on Assets | -948.95% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · BCDA · BFRI · CHEK · GBS
Explore sector: Healthcare · Medical - Devices
More sections of PFSA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks